focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRBS.L Regulatory News (RBS)

  • There is currently no data for RBS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Share Redemption

30 Jul 2015 07:02

RNS Number : 5062U
Royal Bank of Scotland Group PLC
30 July 2015
 



THE ROYAL BANK OF SCOTLAND GROUP PLC

Redemption of American Depositary Shares Representing Non-Cumulative USD Preference Shares Series M, N, P and Q

30 July 2015

The Royal Bank of Scotland Group plc ("RBSG") has given notice to holders of the redemption on 1 September 2015 (the "Redemption Date"), in whole, of the following series of Non-cumulative USD Preference Shares and the corresponding series of American Depositary Shares ("ADSs"):

(i) Non-cumulative USD Preference Shares, Series M (ADS CUSIP: 780097796; ADS ISIN: US7800977966), amount outstanding US$578,146,725 (the "Series M preference shares");

(ii) Non-cumulative USD Preference Shares, Series N (ADS CUSIP: 780097770; ADS ISIN: US7800977701), amount outstanding US$552,829,000 (the "Series N preference shares");

(iii) Non-cumulative USD Preference Shares, Series P (ADS CUSIP: 780097762; ADS ISIN: US7800977628), amount outstanding US$247,082,675 (the "Series P preference shares"); and

(iv) Non-cumulative USD Preference Shares, Series Q (ADS CUSIP: 780097754; ADS ISIN: US7800977545), amount outstanding US$516,173,450 (the "Series Q preference shares", and together with the Series M preference shares, the Series N preference shares and the Series P preference shares, the "Preference Shares"),

at the redemption price, with respect to each series of Preference Shares and the corresponding series of ADSs, of US$25.00 per Preference Share and per ADS plus accrued dividends for the current dividend period to the Redemption Date, which dividend shall equal $0.275556 per Series M preference share, $0.273403 per Series N preference share, $0.269097 per Series P preference share and $0.290625 per Series Q preference share. The redemption amount with respect to each series of Preference Shares shall be paid out of distributable profits of RBSG. The Preference Shares will cease to accrue dividends and shall be cancelled and all unmatured dividend coupons and talons (if any) shall become void for any purpose, as from the Redemption Date. 

On the Redemption Date, the depositary for the American depositary receipts evidencing the ADSs will redeem the number of ADSs corresponding to the relevant Preference Shares being redeemed at a price per ADS equal to the per share amount received by the depositary upon redemption of the relevant Preference Shares. As from the Redemption Date, the holders of the ADSs representing each series of Preference Shares will, upon surrender of the ADSs, be entitled to receive funds deposited with The Bank of New York Mellon as depositary with respect to the Preference Shares of that series, without interest. The ADSs will cease to trade on the New York Stock Exchange from the Redemption Date.

Holders of the ADSs should read the notice relating to the redemption of the relevant series of Preference Shares and Letter of Transmittal included in such notice for information on the actions that they need to undertake to receive the redemption proceeds.

For further information and copies of the notices and Letters of Transmittal, please contact:

The Bank of New York Mellon (depositary) at telephone number 1 866 300 4353; international callers may telephone +001 201 680 6825.

 

 

The Royal Bank of Scotland Group plc:

 

RBS Investor Relations

Matthew Richardson

Head of Debt Investor Relations

Tel: +44 (0) 20 7678 1800

 

 

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those related to RBS and its subsidiaries' regulatory capital position, risk-weighted assets, impairment losses and credit exposures under certain specified scenarios. In addition, forward-looking statements may include, without limitation, statements typically containing words such as "intends", "expects", "anticipates", "targets", "plans", "estimates" and words of similar import. These statements concern or may affect future matters, such as RBSG's future economic results, business plans and current strategies. Forward-looking statements are subject to a number of risks and uncertainties that might cause actual results and performance to differ materially from any expected future results or performance expressed or implied by the forward-looking statements. Factors that could cause or contribute to differences in current expectations include, but are not limited to, legislative, fiscal and regulatory developments, competitive conditions, technological developments, exchange rate fluctuations and general economic conditions. These and other factors, risks and uncertainties that may impact any forward-looking statement or RBSG's actual results are discussed in RBSG's UK Annual Report and materials filed with, or furnished to, the US Securities and Exchange Commission, including, but not limited to, RBSG's Reports on Form 6-K and most recent Annual Report on Form 20-F. The forward-looking statements contained in this announcement speak only as of the date of this announcement and RBSG does not assume or undertake any obligation or responsibility to update any of the forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, except to the extent legally required.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLFFLVDLIAFIE
Date   Source Headline
17th Apr 201911:20 amRNSSegmental Reporting Restatement Document
1st Apr 20194:30 pmRNSDirector/PDMR Shareholding
29th Mar 20195:04 pmRNSTotal Voting Rights
27th Mar 20192:05 pmRNSPublication of Final Terms
20th Mar 201910:17 amRNSRBSG pricing of US$2 billion of Senior Notes
19th Mar 20198:30 amRNSMorgan Stanley European Financials Conference
13th Mar 20196:26 pmRNSNotice of Redemption
11th Mar 20193:00 pmRNSDirector/PDMR Shareholding
7th Mar 20194:56 pmRNSForm 8.3 - Findel plc
6th Mar 20192:45 pmRNSForm 8.3 - MedicX Fund Limited
1st Mar 20191:10 pmRNSForm 8.3 - MedicX Fund Limited
1st Mar 201912:01 pmRNSDirector/PDMR Shareholding
1st Mar 20197:00 amRNSFiling of Annual Report on Form 20-F with US SEC
28th Feb 20192:25 pmRNSDividend Declaration
28th Feb 201912:40 pmRNSTotal Voting Rights
26th Feb 20195:50 pmRNSPublication of Supplementary Prospectus
22nd Feb 201912:51 pmRNSUpdate on NatWest Markets transfer scheme
22nd Feb 201912:00 pmRNSDirector/PDMR Shareholding
15th Feb 20193:00 pmRNSPublication of Supplementary Prospectus
15th Feb 20197:02 amRNSDirectorate Change
15th Feb 20197:01 amRNSAnnual Financial Report
15th Feb 20197:00 amRNSFinal Results
6th Feb 20194:16 pmRNSResult of Meeting
6th Feb 20192:55 pmRNSGM Statement
31st Jan 201911:42 amRNSTotal Voting Rights
29th Jan 20192:55 pmRNSDirector/PDMR Shareholding
25th Jan 20191:27 pmRNSForm 8.3 Disclosure
17th Jan 20194:10 pmRNSNotice of GM
9th Jan 20195:02 pmRNSHolding(s) in Company
31st Dec 20181:13 pmRNSTotal Voting Rights
28th Dec 20184:28 pmRNSDirector/PDMR Shareholding
27th Dec 20184:55 pmRNSDividend Declaration
18th Dec 20183:55 pmRNSDirectorate Change
14th Dec 20186:15 pmRNSRBS welcome credit ratings action by Fitch Ratings
14th Dec 20183:33 pmRNSPublication of a Prospectus
6th Dec 20184:40 pmRNSSecond Price Monitoring Extn
6th Dec 20184:35 pmRNSPrice Monitoring Extension
6th Dec 20182:16 pmRNSNatWest Markets transfer scheme
30th Nov 20182:30 pmRNSTotal Voting Rights
30th Nov 20181:12 pmRNSDirector/PDMR Shareholding
29th Nov 20184:28 pmRNSDividend Declaration
29th Nov 20184:07 pmRNSNotice of Redemption
29th Nov 201811:34 amRNSNotice of Rdemption
29th Nov 201811:33 amRNSNotice of Redemption
29th Nov 201811:31 amRNSNotice of Redemption
29th Nov 201811:31 amRNSNotice of Redemption
29th Nov 20188:00 amRNSRBS Investor Seminar: Commercial Banking
28th Nov 20185:09 pmRNS2018 Bank of England stress test results
16th Nov 201812:00 pmRNSDirector/PDMR Shareholding
9th Nov 20184:16 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.